Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.74 |
| ▸ | RAF1 | P04049 | 14/20 | 0.74 |
| ▸ | BRAF | P15056 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29843015 | 1.00 | MAP2K1 (0.74) | MAP2K1RAF1BRAFCYP3A4CYP2C9 | |
| SCHEMBL960731 | 0.91 | MAP2K1 (0.62) | MAP2K1RAF1BRAFCYP3A4CYP2C9 | |
| SCHEMBL958935 | 0.90 | MAP2K1 (0.62) | MAP2K1RAF1BRAFCYP3A4CYP2C9 | |
| SCHEMBL12694081 | 0.90 | MAP2K1 (0.75) | MAP2K1RAF1BRAFCYP3A4CYP2C9 | |
| SCHEMBL26237957 | 0.89 | MAP2K1 (0.60) | MAP2K1RAF1BRAFCYP3A4CYP2C9 | |
| SCHEMBL18699238 | 0.88 | MAP2K1 (0.81) | MAP2K1RAF1BRAFCYP3A4CYP2C9 | |
| SCHEMBL14048893 | 0.87 | MAP2K1 (0.70) | MAP2K1RAF1BRAFCYP3A4CYP2C9 | |
| SCHEMBL960507 | 0.86 | MAP2K1 (0.76) | MAP2K1RAF1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL29843095 | 0.86 | MAP2K1 (0.76) | MAP2K1RAF1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL959125 | 0.86 | MAP2K1 (0.69) | MAP2K1RAF1BRAFCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235356-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023108110-A2 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023081676-A1 | METHODS OF TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023076991-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230119327-A1 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | IMMUNEERING CORPORTAION | 2023-04-20 | — | — | US | disclosed |
| EP-2172198-B1 | p27 PROTEIN INDUCER | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8278465-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-02 | — | — | US | disclosed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119327-A1 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | BRAF, NRAS, RAF1 | MAP2K1 57/4885RAF1 3/4885BRAF 1/4885 |
| US-20110009398-A1 | p27 Protein Inducer | CDKN1A, CDK2, SKP2 | MAP2K1 1179/4885RAF1 1656/4885BRAF 2611/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | MAP2K1 3163/4885RAF1 438/4885BRAF 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.